These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 7770366)

  • 21. Clinical safety profile of sotalol in patients with arrhythmias.
    Soyka LF; Wirtz C; Spangenberg RB
    Am J Cardiol; 1990 Jan; 65(2):74A-81A; discussion 82A-83A. PubMed ID: 2403737
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monotherapy versus combination therapy with class III antiarrhythmic agents to attenuate transmural dispersion of repolarization: a potential risk factor for torsade de pointes.
    Shah SA; Kluger J; White CM
    Pharmacotherapy; 2007 Sep; 27(9):1297-305. PubMed ID: 17723083
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management.
    Hohnloser SH
    Am J Cardiol; 1997 Oct; 80(8A):82G-89G. PubMed ID: 9354415
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Electrophysiologic basis for the antiarrhythmic actions of sotalol and comparison with other agents.
    Singh BN
    Am J Cardiol; 1993 Aug; 72(4):8A-18A. PubMed ID: 8346731
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mexiletine antagonizes effects of sotalol on QT interval duration and its proarrhythmic effects in a canine model of torsade de pointes.
    Chézalviel-Guilbert F; Davy JM; Poirier JM; Weissenburger J
    J Am Coll Cardiol; 1995 Sep; 26(3):787-92. PubMed ID: 7642874
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expanding clinical role of unique class III antiarrhythmic effects of sotalol.
    Singh BN
    Am J Cardiol; 1990 Jan; 65(2):84A-88A. PubMed ID: 2403738
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sotalol.
    Hohnloser SH; Woosley RL
    N Engl J Med; 1994 Jul; 331(1):31-8. PubMed ID: 8202100
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evolving role of sotalol in the management of ventricular tachyarrhythmias.
    O'Callaghan PA; McGovern BA
    Am J Cardiol; 1996 Aug; 78(4A):54-60. PubMed ID: 8780329
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is class III antiarrhythmic activity important?
    Singh BN
    Cardiovasc Drugs Ther; 1990 Jun; 4 Suppl 3():597-602. PubMed ID: 2275889
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New antiarrhythmic drug in pediatric use: sotalol.
    Pfammatter JP; Paul T
    Pediatr Cardiol; 1997; 18(1):28-34. PubMed ID: 8960489
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of sotalol for therapy of complex ventricular arrhythmias and comparisons with placebo and class I antiarrhythmic drugs.
    Anderson JL
    Am J Cardiol; 1990 Jan; 65(2):37A-42A; discussion 51A-52A. PubMed ID: 2403734
    [TBL] [Abstract][Full Text] [Related]  

  • 32. From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials.
    Lazzara R
    Am J Cardiol; 1996 Aug; 78(4A):28-33. PubMed ID: 8780326
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Electrophysiologic properties of sotalol and d-sotalol. A current view.
    Touboul P
    Eur Heart J; 1993 Nov; 14 Suppl H():24-9. PubMed ID: 7904935
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Torsade de pointes complicating drug treatment of low-malignant forms of arrhythmia: four cases reports.
    Faber TS; Zehender M; Van de Loo A; Hohnloser S; Just H
    Clin Cardiol; 1994 Apr; 17(4):197-202. PubMed ID: 8187370
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Arrhythmia control by prolonging repolarization: the concept and its potential therapeutic impact.
    Singh BN
    Eur Heart J; 1993 Nov; 14 Suppl H():14-23. PubMed ID: 7904934
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and proarrhythmia of oral sotalol in pediatric patients.
    Pfammatter JP; Paul T; Lehmann C; Kallfelz HC
    J Am Coll Cardiol; 1995 Oct; 26(4):1002-7. PubMed ID: 7560592
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Short- and long-term antiarrhythmic and hemodynamic effects of d,l-sotalol in patients with symptomatic ventricular arrhythmias.
    Hohnloser SH; Zabel M; Krause T; Just H
    Am Heart J; 1992 May; 123(5):1220-4. PubMed ID: 1575137
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of sotalol in patients with drug-refractory sustained ventricular tachyarrhythmias.
    Kehoe RF; Zheutlin TA; Dunnington CS; Mattioni TA; Yu G; Spangenberg RB
    Am J Cardiol; 1990 Jan; 65(2):58A-64A; discussion 65A-66A. PubMed ID: 2294689
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Electrophysiological effects of MS-551, a new class III agent: comparison with dl-sotalol in dogs.
    Sen L; Cui G; Sakaguchi Y; Singh BN
    J Pharmacol Exp Ther; 1998 May; 285(2):687-94. PubMed ID: 9580614
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sotalol: a new class III antiarrhythmic agent.
    Zanetti LA
    Clin Pharm; 1993 Dec; 12(12):883-91. PubMed ID: 8137605
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.